Second-generation CK2 alpha inhibitors targeting the alpha D pocket.Iegre, J., Brear, P., De Fusco, C., Yoshida, M., Mitchell, S.L., Rossmann, M., Carro, L., Sore, H.F., Hyvonen, M., Spring, D.R.
(2018) Chem Sci 9: 3041-3049
- PubMed: 29732088
- DOI: 10.1039/c7sc05122k
- Primary Citation of Related Structures:
- PubMed Abstract:
CK2 is a critical cell cycle regulator that also promotes various anti-apoptotic mechanisms. Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kina ...
CK2 is a critical cell cycle regulator that also promotes various anti-apoptotic mechanisms. Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases. We have previously utilised a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066 . Whilst CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site. This second generation αD-site binding inhibitor, compound CAM4712 (IC 50 = 7 μM, GI 50 = 10.0 ± 3.6 μM), has numerous advantages over the previously reported CAM4066 , including a reduction in the number of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability. Unlike with CAM4066 , there was no need to facilitate cellular uptake by making a prodrug. Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC 50 ) and the ability to inhibit cell proliferation (GI 50 ).
R&D Division , Daiichi Sankyo Co., Ltd. , 1-2-58, Hiromachi, Shinagawa-ku , Tokyo 140-8710 , Japan.,Department of Chemistry , University of Cambridge , CB2 1EW , Cambridge , UK . Email: email@example.com.,Department of Biochemistry , University of Cambridge , CB2 1GA , Cambridge , UK . Email: firstname.lastname@example.org.,Structure Biophysics & FBLG , Discovery Sciences , IMED Biotech Unit , AstraZeneca , Cambridge , UK.